Table 1 Subject characteristics.

From: Myocardial Effective Transverse Relaxation Time T 2 * is Elevated in Hypertrophic Cardiomyopathy: A 7.0 T Magnetic Resonance Imaging Study

Parameter

HCM Patients

Healthy Controls

P Value

n

6

6

 

Sex (male/female)

4/2

4/2

 

Age, y

52.7 ± 17.5

50 ± 12.4

0.77

Height, cm

170 ± 10

172 ± 8

0.71

Weight, kg

73.12 ± 9.6

71.5 ± 14.1

0.82

BMI, kg/m2

25.19 ± 1.9

23.9 ± 2.9

0.39

BSA, m2

1.84 ± 0.18

1.84 ± 0.21

0.97

Systolic blood pressure, mmHG

142.3 ± 22.8

135.5 ± 14.9

0.56

Diastolic blood pressure, mmHG

85.8 ± 17.5

86.3 ± 13.6

0.96

Heart rate, min−1

65.17 ± 10.83

71.7 ± 9.8

0.30

Mean end-systolic septal wall thickness, mm

16.6 ± 1.8

9.8 ± 1.4

0.001*

Mean end-diastolic septal wall thickness, mm

13.0 ± 3.1

6.2 ± 1.2

0.002*

Mean T2* averaged across all phases, ms

17.4 ± 1.4

13.7 ± 1.1

0.001*

Mean end-systolic septal T2*, ms

17.7 ± 1.2

15.0 ± 2.1

0.025*

Mean end-diastolic septal T2*, ms

16.2 ± 2.5

13.4 ± 1.3

0.039*

LVEDV, ml

128.8 ± 33.3

121.02 ± 21.88

0.64

LVESV, ml

51.3 ± 20.0

49.35 ± 12.96

0.85

LVEF

60.9 ± 8.5

59.3 ± 6.3

0.47

LV mass, g

168.9 ± 68.0

93.1 ± 17.0

0.041*

Presence of late gadolinium enhancement

6/6

—

 
  1. Values are given as mean ± standard deviation. The P value stems from a student’s t-test except for LVEF where it stems from a Mann-Whitney u-test. BMI, body mass index; BSA, body surface area; *P < 0.05.
Back to article page